78% of mental health disability claimants are on the wrong medication. That's a fixable problem.
Mental health disability claims are the leading cost driver for Canadian plan sponsors, and they are getting longer. Pillcheck is the only pharmacogenomics (PGx) service in Canada built to address both the clinical and the operational sides of this problem. It combines proven outcomes data with a complete service model designed for group benefits integration.
The problem every plan sponsor is watching
Global disability insurers reported benefit ratio pressure in Q2 2026. Unum’s UK Group Income Protection book deteriorated 720 basis points year over year on higher claim severity and incidence. In Canada’s group LTD market, mental health has been the leading driver of absence and long-term disability for years, and the trend continues upward.
The reason is not simply that more people are developing mental health conditions. It is that finding effective treatment takes too long.
An analysis of LTD claimants with mental health diagnoses found that only 22% had normal activity of the enzymes that metabolize the 55 drugs most commonly prescribed for mental health management. The remaining 78% carry genetic variants that lead to adverse reactions, side effects, or medication failure. Each failed drug trial takes a minimum of eight weeks. That means eight more weeks of impairment, benefit payments, and time away from work.
There isn’t much organizations can do to fix this through case management alone. Treatment optimization is a clinical problem that requires a clinical tool. Pillcheck is that tool, and it is proven to deliver durable value at every stage of the health and wellness continuum.
Why generic wellness investments fall short
Most employee wellness programs measure engagement, not outcomes. App logins, session completions, and survey scores tell plan sponsors that members are using a service. They do not show whether health is improving or whether a disability claim was avoided.
Pillcheck works differently. Every Pillcheck is anchored in an evidence-based output: a pharmacist opinion letter that gives the treating physician specific, actionable recommendations on drug selection and dosing. These recommendations draw on the member’s genetic profile, medication history, health conditions, and treatment experience.
It is a clinical decision-support tool delivered at scale, using a model proven in a randomized controlled trial.
The evidence base: proven in a Canadian RCT
In a randomized controlled trial published in Clinical and Translational Science (Papastergiou et al., 2021) and sponsored by GreenShield Canada, 213 patients with major depressive disorder and/or generalized anxiety disorder were randomized to either pharmacogenomics-guided treatment using Pillcheck or standard care.
The results were as follows.
- Depression outcomes improved significantly more in the PGx-guided group.
- Generalized anxiety outcomes improved significantly more in the PGx-guided group.
- Disability scores improved significantly more in the PGx-guided group, as measured by the validated Sheehan Disability Scale.
- Physicians accepted the vast majority of Pillcheck-pharmacist recommendations.
That third finding is the most critical for plan sponsors and disability managers. Not only does Pillcheck-guided care improve how patients feel, but it also measurably shortens the period of functional impairment that shapes a disability claim.
A separate cohort analysis of LTD claimants with mental health conditions (Litinski, Benefits and Pensions Monitor, 2021) showed that pharmacogenomics-guided care also helped plan sponsors avoid the cost of ineffective, sometimes harmful prescriptions and the lost productivity that follows.
A complete service, not just a test
Pillcheck goes beyond a diagnostic test. It’s a fully integrated pharmacogenomics service delivering meaningful clinical value throughout the member’s health journey.
What every Pillcheck includes
- Clinical-grade genetic test. A simple, non-invasive cheek swab is processed in a certified laboratory using validated methods. The panel captures Tier 1 and Tier 2 genetic variants under Association for Molecular Pathology (AMP) guidelines, including copy number variant (CNV) analysis of CYP2D6.
- Personalized Pillcheck report. A clear, structured report covering more than 350 medications across mental health, pain, cardiovascular, gastroenterology, neurology, women’s health, oncology, and other areas. Medications are grouped by level of gene-drug interaction, with plain-language interpretation for use in a clinical conversation.
- Expert pharmacist opinion letter. A PGx-trained pharmacist reviews the genetic profile alongside the member’s current and past medications, health conditions, supplements, and treatment history. The letter gives the prescribing physician specific, actionable recommendations on drug selection and dosing. It also flags drug-drug interactions that may override or modify genetics-based guidance. The Pillcheck Pharmacist Review is the clinical handoff that changes prescribing decisions.
- Secure sharing portal. Members share results with any healthcare provider they choose through a secure digital portal. Case managers, disability managers, and treating physicians can access the same clinical information, which reduces administrative friction in return-to-work planning.
- Lifetime report updates. As pharmacogenomics guidelines expand, new medications are added to the member’s report at no additional cost. Because DNA does not change, the profile stays valid for every future medication decision, whether that is a cardiovascular prescription, a pain management protocol, or a psychiatric adjustment years later.
- Ongoing pharmacist access. Members can contact their reviewing pharmacist for clarification as new medications are considered. This creates continuity of clinical support across the member’s health history. New Pharmacist Reviews can be ordered when there are significant changes in health status or prescriptions.
Learn more: More about Pillcheck
Workflow integration for case managers
Disability case managers need clinical intelligence that is timely, actionable, and easy to fold into existing workflows. Pillcheck is designed to deliver all three.
When a member already has a Pillcheck profile, the case manager opens a new claim with the pharmacist opinion letter already in hand. There is no wait for a new test and no delay in clinical context. For members without a prior profile, Pillcheck can be ordered and completed within the first weeks of a claim. Results are typically available within 5-10 business days of the lab receiving the sample. That timing lets clinical guidance inform treatment decisions before the claim moves into the LTD phase.
The Pillcheck Pharmacist Review’s structure reflects what healthcare practitioners need to know: which medications may be impairing function, whether dose adjustments or medication changes are warranted, and recommendations from an expert pharmacist specializing in pharmacogenetics.
Efficiency and workflow touchpoints
- Proactive enrollment through an extended health or wellness benefit
- Triggered ordering for members with mental health or chronic pain diagnoses
- Pharmacist opinion letter shared with the treating physician and the claimant
- Pharmacist available for claimant or physician consultation on complex medication questions
Implementation KPIs and ROI framework
Pillcheck deployments are measurable. Plan sponsors that integrate Pillcheck into their benefits strategy can track outcomes against defined KPIs at both the individual and the population level.
Cost-effectiveness benchmark
At $599 per member, Pillcheck costs less than a single week of LTD benefit payments for a median-salary employee. That price covers a lifetime clinical asset spanning more than 350 medications, a pharmacist review, and ongoing updates. The break-even on avoided claim duration is measurable within the first year of deployment at scale.
The whole-person health intelligence advantage
Pillcheck creates a longitudinal clinical record for each member that continues to inform care over time. A member’s genetic profile, medication history, and pharmacist’s structured assessment combine to form a personalized “medications passport,” an easy-to-use clinical reference that can be revisited as medications, health needs, and treatment goals change. This information can support decisions across mental health, cardiovascular health, chronic pain, metabolic conditions, and women’s health, rather than being limited to a single condition or point in time.
This is whole-person health guidance with long-term value for the member. A person can carry forward a clinically relevant medication profile that helps make future medication decisions more precise, more efficient, and more likely to succeed on the first try. Internal KPI tracking shows that members repeatedly return to view their Pillcheck results (about every 6 months on average), demonstrating that the clinical value compounds well beyond the initial test.
For plan sponsors investing in longevity and chronic disease prevention, a new Pillcheck workplace program adds a durable clinical layer to support proactive health management throughout the member’s health journey—turning an episodic intervention into an ongoing source of measurable value.
Accessible across Canada, including remote and underserved communities
Through a partnership with North West Telepharmacy Solutions, PGx-guided pharmacist reviews are available to plan members across Canada. That includes remote, rural, and Indigenous communities where specialist access is limited. Telepharmacy delivery means the clinical quality of the Pillcheck service remains consistent regardless of geography. For national plan sponsors and for carriers managing diverse member populations, that consistency is a critical equity consideration.
The bottom line for plan sponsors
Pillcheck delivers on three commitments that no other pharmacogenomics service in Canada has demonstrated together.
- Proven outcomes. RCT-validated improvement in depression, anxiety, and disability scores, with physician acceptance of pharmacist recommendations at scale.
- Complete service. Genetic testing, expert pharmacist review, a physician-facing clinical letter, secure sharing, and lifetime updates in a single, fixed-cost program.
- Measurable ROI. Defined KPIs, cohort-level outcomes tracking, and a cost structure that makes break-even analysis straightforward for any plan sponsor.
Mental health disability claims will not resolve themselves. But they can be shortened, and some can be prevented, by getting the right medication to the right person faster. That is what Pillcheck does.
To learn how Pillcheck integrates with your group benefits plan or disability management program, contact our team or visit our healthcare provider resources.
References
Papastergiou J, Quilty LC, Li W, et al. Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: a randomized controlled trial. Clin Transl Sci. 2021;14(4):1359–1368.
Litinski V. Speeding up plan evolution: COVID and pharmacogenetics. Benefits and Pensions Monitor. February 2021.
Pharmacogenetic Testing May Improve Drug Treatments and Shorten Disability Leaves. By: Lefaivre, Antoine; Litinski, Veronika; Vandenhurk, Maria. Benefits Quarterly, 2017, v. 33, p. 43, ISSN 8756-1263.
